Gao Yunyun, Gao Yang, Yin Fei, Wang Mi, Wang Zhenhong, Ye Tiantian, Yang Yonggang, Pan W S, Yang Xinggang
a Department of Pharmaceutics, School of Pharmacy , Shenyang Pharmaceutical University , Shenyang , Liaoning , China .
Drug Dev Ind Pharm. 2015;41(9):1443-51. doi: 10.3109/03639045.2014.956113. Epub 2015 Jul 21.
The purpose of this research aimed at preparing gastro-floating sustained-release tablets of troxipide and a further study on in vitro release and in vivo bioavailability. Under the circumstances of direct powder compression, the floating tablets were successfully prepared with HPMC as main matrix material, Carbopol as assistant matrix material, octadecanol as floating agent and sodium bicarbonate as foaming agent to float by gas-forming. The floating time and accumulative release amount as evaluation indexes were utilized to perform pre-experiment screening and single-factor test, respectively, while central composite design response surface method was applied for formulation optimization, followed by in vivo pharmacokinetic study in beagles after oral administration for floating tablets and commercial tablets used as the control. The results indicated that the floating sustained-release tablets held a better capability for floating and drug release and more satisfactory pharmacokinetic parameters, such as a lower Cmax, a prolonged Tmax, but an equivalent bioavailability calculated by AUC0-24 compared to commercial tablets. So a conclusion was finally drawn that the floating sustained-release tablets possessing a good release property could be suitable for demands of design.
本研究旨在制备曲昔派特胃漂浮缓释片,并对其体外释放度和体内生物利用度进行进一步研究。在直接粉末压片的情况下,以羟丙甲纤维素(HPMC)为主要基质材料、卡波姆为辅助基质材料、十八醇为漂浮剂、碳酸氢钠为发泡剂通过产气实现漂浮,成功制备了漂浮片。分别以漂浮时间和累积释放量为评价指标进行预实验筛选和单因素试验,同时采用中心复合设计响应面法进行处方优化,随后以市售片为对照,对漂浮片进行犬口服给药后的体内药代动力学研究。结果表明,胃漂浮缓释片具有较好的漂浮和释药能力,药代动力学参数更理想,如Cmax较低、Tmax延长,但与市售片相比,通过AUC0-24计算的生物利用度相当。最终得出结论,具有良好释药性能的胃漂浮缓释片能够满足设计要求。